News

TB R&D Weekly Update: Combined Isoniazid and Antiretroviral Therapy Protects HIV-infected Children

Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011 Apr 2. [Epub ahead of print]

This week, the focus is on pediatrics and tuberculosis with several studies published on the subject. Frigati, et al., wanted to determine if isoniazid preventive therapy (IPT) combine with antiretroviral therapy (ART) would reduce TB in HIV-infected children. In previous research, combining IPT and ART showed a 76% reduction in risk of TB in HIV-infected adults compared to those not on either treatment.

The study found that that IPT combined with ART greatly reduced the risk of TB significantly compared to children receiving only IPT or only ART. This finding could have implications for policy recommendations for children on ART. The screening of children for active TB disease is important to reduce the emergence of resistance. Other interesting points include:

  • Infants with HIV have a 24-fold higher risk of getting TB than infants without HIV infection.
  • Children with HIV and TB have a greater risk of more severe disease, progressing more rapidly to disease, and death.
  • The finding from the study, which took place in South Africa, may not apply to low TB prevalence settings.
  • For the analysis, Cox proportional hazards regression was used and hazard ratios generated.
  • Since young children are more likely to develop disease from a primary infection and not reactivation of latent infections, IPT may help contain primary infection in children receiving ART.

Additional TB R&D News:

Multi-drug Resistant Childhood Tuberculosis

Pharmacokinetics of Anti-tuberculosis Drugs in Children

Management of Tuberculosis in Children and New Treatment Options

India, Spain JV biotech plant inaugurated

New Database to Help Track Quality of Medicines in Global Markets


More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...